A number of firms have modified their ratings and price targets on shares of AbbVie (NYSE: ABBV) recently: 6/23/2016 – AbbVie was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $67.78 price target on the stock. 6/16/2016 – AbbVie was downgraded by analysts at Vetr from […]
